Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | G6PD | P11413 | 2/20 | 1.00 |
| ▸ | MPI | P34949 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | RUNX1 | Q01196 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL29357338 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL11687749 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL29362693 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| (S)Apomorphine SCHEMBL19469972 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL29737448 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL5904190 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL1321033 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL21410343 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL21846961 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL232473 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2629 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735988-B1 | SUBLINGUAL FILMS | SUMITOMO PHARMA AMERICA INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-4578461-A2 | METHODS OF TREATING PARKINSONS DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA | Sumitomo Pharma America, Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| EP-2442650-B2 | SUBLINGUAL APOMORPHINE | SUNOVION PHARMACEUTICALS INC (US) | 2025-05-14 | — | — | EP | claimed |
| WO-2025049966-A9 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025049966-A2 | METHODS AND COMPOSITIONS FOR INCREASING ROR1 EXPRESSION | WASIK MARIUSZ A (US) | 2025-03-06 | — | — | WO | claimed |
| EP-3285771-B1 | METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA | SUNOVION PHARMACEUTICALS INC (US) | 2025-02-12 | — | — | EP | claimed |
| US-20250000855-A1 | USE OF APOMORPHINE AS THERAPEUTIC AGENT FOR NECROPTOSIS-RELATED DISEASES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2025-01-02 | — | — | US | claimed |
| EP-3638673-B9 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-20 | — | — | EP | claimed |
| EP-4427749-A1 | USE OF APOMORPHINE AS THERAPEUTIC AGENT FOR NECROPTOSIS-RELATED DISEASES | Industry-Academic Cooperation Foundation, Yonsei University (KR) | 2024-09-11 | — | — | EP | claimed |
| EP-4398908-A2 | TREATMENT OF NEUROLOGICAL DISORDERS | GMP Biotechnology Limited (CN) | 2024-07-17 | — | — | EP | claimed |
| WO-1999065475-A2 | COMBINATION OF PHENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION | SCHERING CORPORATION (US) | 1999-12-23 | — | — | WO | claimed |
| US-6001845-A | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | SCHERING CORPORATION (US) | 1999-12-14 | — | — | US | claimed |
| WO-1999015161-A2 | INHIBITION OF PSYCHOSTIMULANT-INDUCED AND NICOTINE-INDUCED CRAVING | THE GENERAL HOSPITAL CORPORATION (US) | 1999-04-01 | — | — | WO | claimed |
| US-5888534-A | SUSTAINED RELEASE OF WATER SOLUBLE DRUGS | PENTECH PHARMACEUTICALS, INC. (US) | 1999-03-30 | — | — | US | claimed |
| WO-1998048781-A1 | CONTROLLED RELEASE OF DRUGS DELIVERED BY SUBLINGUAL OR BUCCAL ADMINISTRATION | PENTECH PHARMACEUTICALS, INC. (US) | 1998-11-05 | — | — | WO | claimed |
| US-5756483-A | TREATMENT OF PARKINSON'S DISEASE | MERKUS FRANCISCUS W H M (BE) | 1998-05-26 | — | — | US | claimed |
| US-5624677-A | APOMORPHINE | PENTECH PHARMACEUTICALS, INC. (US) | 1997-04-29 | — | — | US | claimed |
| US-5562917-A | INCLUDES WATER SOLUBLE METHYL CELLULOSE-TYPE GEL, AND WATER | PENTECH PHARMACEUTICALS, INC. (US) | 1996-10-08 | — | — | US | claimed |
| EP-0689438-A1 | PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF DIHYDROERGOTAMINE, APOMORPHINE AND MORPHINE | Merkus, Franciscus Wilhelmus Henricus Maria (BE) | 1996-01-03 | — | — | EP | claimed |
| WO-1994022445-A2 | PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF DIHYDROERGOTAMINE, APOMORPHINE AND MORPHINE | MERKUS FRANCISCUS W H M (BE) | 1994-10-13 | — | — | WO | claimed |